Inflammatory Bowel Disease Treatment Market Forecast to 2027 - Covid-19 Impact and Global Analysis - by Drug Class (Aminosalicyclates, Immunomodulators, TNF Inhibitors, Corticosteroids); Disease Indication (Crohn's Disease, Ulcerative Colitis); Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
Report Code: TIPRE00003491 No. of Pages: 150 Category: Pharmaceuticals Status: Upcoming
MARKET INTRODUCTION
Inflammatory bowel disease (IBD) is a term which is used to describe the disorders that involve chronic inflammation of the digestive tract. The two types of IBD include namely, ulcerative colitis and crohn's disease that usually involve severe diarrhea, abdominal pain, fatigue and weight loss. The treatment of the IBD is to reduce the inflammation that triggers your signs and symptoms. The treatment involve the drug therapy or surgery. Drugs therapy include, Anti-inflammatory drugs that further include corticosteroids and aminosalicylates such as, mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum), depending upon the affected area of colon.
MARKET DYNAMICS
The inflammatory bowel disease treatment market is anticipated to grow in the forecast period owing to driving factors such as, increase in intake of unhealthy food and beverages along with the stressful lifestyle. However, increasing prevalence of crohn's disease and ulcerative colitis is anticipated to offer more growth opportunities for the players operating in the inflammatory bowel disease treatment market.
MARKET SCOPE
The "Global Inflammatory Bowel Disease Treatment Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of inflammatory bowel disease treatment market with detailed market segmentation by drug class type, disease indication, distribution channel and geography. The global inflammatory bowel disease treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading inflammatory bowel disease treatment market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global inflammatory bowel disease treatment market is segmented on the basis of drug class type, disease indication, distribution channel. Based on drug class type, the market is segmented as, aminosalicyclates, immunomodulators, TNF inhibitors, and corticosteroids. On the basis of disease indication, the market is segmented into crohn's disease and others. Based on the end user, the global inflammatory bowel disease treatment market is classified as, hospital pharmacy, online pharmacy, and retail pharmacy.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global inflammatory bowel disease treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The inflammatory bowel disease treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting inflammatory bowel disease treatment market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the inflammatory bowel disease treatment market in these regions.
MARKET PLAYERS
The reports cover key developments in the inflammatory bowel disease treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from inflammatory bowel disease treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for inflammatory bowel disease treatment market in the global market. Below mentioned is the list of few companies engaged in the inflammatory bowel disease treatment market.
The report also includes the profiles of key inflammatory bowel disease treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Inflammatory bowel disease (IBD) is a term which is used to describe the disorders that involve chronic inflammation of the digestive tract. The two types of IBD include namely, ulcerative colitis and crohn's disease that usually involve severe diarrhea, abdominal pain, fatigue and weight loss. The treatment of the IBD is to reduce the inflammation that triggers your signs and symptoms. The treatment involve the drug therapy or surgery. Drugs therapy include, Anti-inflammatory drugs that further include corticosteroids and aminosalicylates such as, mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum), depending upon the affected area of colon.
MARKET DYNAMICS
The inflammatory bowel disease treatment market is anticipated to grow in the forecast period owing to driving factors such as, increase in intake of unhealthy food and beverages along with the stressful lifestyle. However, increasing prevalence of crohn's disease and ulcerative colitis is anticipated to offer more growth opportunities for the players operating in the inflammatory bowel disease treatment market.
MARKET SCOPE
The "Global Inflammatory Bowel Disease Treatment Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of inflammatory bowel disease treatment market with detailed market segmentation by drug class type, disease indication, distribution channel and geography. The global inflammatory bowel disease treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading inflammatory bowel disease treatment market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global inflammatory bowel disease treatment market is segmented on the basis of drug class type, disease indication, distribution channel. Based on drug class type, the market is segmented as, aminosalicyclates, immunomodulators, TNF inhibitors, and corticosteroids. On the basis of disease indication, the market is segmented into crohn's disease and others. Based on the end user, the global inflammatory bowel disease treatment market is classified as, hospital pharmacy, online pharmacy, and retail pharmacy.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global inflammatory bowel disease treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The inflammatory bowel disease treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting inflammatory bowel disease treatment market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the inflammatory bowel disease treatment market in these regions.
MARKET PLAYERS
The reports cover key developments in the inflammatory bowel disease treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from inflammatory bowel disease treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for inflammatory bowel disease treatment market in the global market. Below mentioned is the list of few companies engaged in the inflammatory bowel disease treatment market.
The report also includes the profiles of key inflammatory bowel disease treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Agilent Technologies, Inc.
- Thermo Fisher Scientific
- Hitachi, Ltd.
- Shimadzu Corporation
- PerkinElmer Inc.
- Hach
- Beckman Coulter, Inc.
- PG Instruments Limited
- JASCO
- B&W Tek
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Inflammatory Bowel Disease Treatment - By Drug Class
1.3.2 Inflammatory Bowel Disease Treatment - By Disease Indication
1.3.3 Inflammatory Bowel Disease Treatment - By Distribution Channel
1.3.4 Inflammatory Bowel Disease Treatment - By Region
1.3.4.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. INFLAMMATORY BOWEL DISEASE TREATMENT LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. INFLAMMATORY BOWEL DISEASE TREATMENT - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. INFLAMMATORY BOWEL DISEASE TREATMENT - GLOBAL MARKET ANALYSIS
6.1. INFLAMMATORY BOWEL DISEASE TREATMENT - GLOBAL MARKET OVERVIEW
6.2. INFLAMMATORY BOWEL DISEASE TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. INFLAMMATORY BOWEL DISEASE TREATMENT - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. AMINOSALICYCLATES
7.3.1. Overview
7.3.2. Aminosalicyclates Market Forecast and Analysis
7.4. IMMUNOMODULATORS
7.4.1. Overview
7.4.2. Immunomodulators Market Forecast and Analysis
7.5. TNF INHIBITORS
7.5.1. Overview
7.5.2. TNF Inhibitors Market Forecast and Analysis
7.6. CORTICOSTEROIDS
7.6.1. Overview
7.6.2. Corticosteroids Market Forecast and Analysis
8. INFLAMMATORY BOWEL DISEASE TREATMENT - REVENUE AND FORECASTS TO 2027 - DISEASE INDICATION
8.1. OVERVIEW
8.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
8.3. CROHN'S DISEASE
8.3.1. Overview
8.3.2. Crohn's Disease Market Forecast and Analysis
8.4. ULCERATIVE COLITIS
8.4.1. Overview
8.4.2. Ulcerative Colitis Market Forecast and Analysis
9. INFLAMMATORY BOWEL DISEASE TREATMENT - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. ONLINE PHARMACY
9.4.1. Overview
9.4.2. Online Pharmacy Market Forecast and Analysis
9.5. RETAIL PHARMACY
9.5.1. Overview
9.5.2. Retail Pharmacy Market Forecast and Analysis
10. INFLAMMATORY BOWEL DISEASE TREATMENT REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Inflammatory Bowel Disease Treatment Overview
10.1.2 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis
10.1.3 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
10.1.4 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
10.1.5 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
10.1.6 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
10.1.6.1 United States Inflammatory Bowel Disease Treatment
10.1.6.1.1 United States Inflammatory Bowel Disease Treatment by Drug Class
10.1.6.1.2 United States Inflammatory Bowel Disease Treatment by Disease Indication
10.1.6.1.3 United States Inflammatory Bowel Disease Treatment by Distribution Channel
10.1.6.2 Canada Inflammatory Bowel Disease Treatment
10.1.6.2.1 Canada Inflammatory Bowel Disease Treatment by Drug Class
10.1.6.2.2 Canada Inflammatory Bowel Disease Treatment by Disease Indication
10.1.6.2.3 Canada Inflammatory Bowel Disease Treatment by Distribution Channel
10.1.6.3 Mexico Inflammatory Bowel Disease Treatment
10.1.6.3.1 Mexico Inflammatory Bowel Disease Treatment by Drug Class
10.1.6.3.2 Mexico Inflammatory Bowel Disease Treatment by Disease Indication
10.1.6.3.3 Mexico Inflammatory Bowel Disease Treatment by Distribution Channel
10.2. EUROPE
10.2.1 Europe Inflammatory Bowel Disease Treatment Overview
10.2.2 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis
10.2.3 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
10.2.4 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
10.2.5 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
10.2.6.1 Germany Inflammatory Bowel Disease Treatment
10.2.6.1.1 Germany Inflammatory Bowel Disease Treatment by Drug Class
10.2.6.1.2 Germany Inflammatory Bowel Disease Treatment by Disease Indication
10.2.6.1.3 Germany Inflammatory Bowel Disease Treatment by Distribution Channel
10.2.6.2 France Inflammatory Bowel Disease Treatment
10.2.6.2.1 France Inflammatory Bowel Disease Treatment by Drug Class
10.2.6.2.2 France Inflammatory Bowel Disease Treatment by Disease Indication
10.2.6.2.3 France Inflammatory Bowel Disease Treatment by Distribution Channel
10.2.6.3 Italy Inflammatory Bowel Disease Treatment
10.2.6.3.1 Italy Inflammatory Bowel Disease Treatment by Drug Class
10.2.6.3.2 Italy Inflammatory Bowel Disease Treatment by Disease Indication
10.2.6.3.3 Italy Inflammatory Bowel Disease Treatment by Distribution Channel
10.2.6.4 Spain Inflammatory Bowel Disease Treatment
10.2.6.4.1 Spain Inflammatory Bowel Disease Treatment by Drug Class
10.2.6.4.2 Spain Inflammatory Bowel Disease Treatment by Disease Indication
10.2.6.4.3 Spain Inflammatory Bowel Disease Treatment by Distribution Channel
10.2.6.5 United Kingdom Inflammatory Bowel Disease Treatment
10.2.6.5.1 United Kingdom Inflammatory Bowel Disease Treatment by Drug Class
10.2.6.5.2 United Kingdom Inflammatory Bowel Disease Treatment by Disease Indication
10.2.6.5.3 United Kingdom Inflammatory Bowel Disease Treatment by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Inflammatory Bowel Disease Treatment Overview
10.3.2 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis
10.3.3 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
10.3.5 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
10.3.6.1 Australia Inflammatory Bowel Disease Treatment
10.3.6.1.1 Australia Inflammatory Bowel Disease Treatment by Drug Class
10.3.6.1.2 Australia Inflammatory Bowel Disease Treatment by Disease Indication
10.3.6.1.3 Australia Inflammatory Bowel Disease Treatment by Distribution Channel
10.3.6.2 China Inflammatory Bowel Disease Treatment
10.3.6.2.1 China Inflammatory Bowel Disease Treatment by Drug Class
10.3.6.2.2 China Inflammatory Bowel Disease Treatment by Disease Indication
10.3.6.2.3 China Inflammatory Bowel Disease Treatment by Distribution Channel
10.3.6.3 India Inflammatory Bowel Disease Treatment
10.3.6.3.1 India Inflammatory Bowel Disease Treatment by Drug Class
10.3.6.3.2 India Inflammatory Bowel Disease Treatment by Disease Indication
10.3.6.3.3 India Inflammatory Bowel Disease Treatment by Distribution Channel
10.3.6.4 Japan Inflammatory Bowel Disease Treatment
10.3.6.4.1 Japan Inflammatory Bowel Disease Treatment by Drug Class
10.3.6.4.2 Japan Inflammatory Bowel Disease Treatment by Disease Indication
10.3.6.4.3 Japan Inflammatory Bowel Disease Treatment by Distribution Channel
10.3.6.5 South Korea Inflammatory Bowel Disease Treatment
10.3.6.5.1 South Korea Inflammatory Bowel Disease Treatment by Drug Class
10.3.6.5.2 South Korea Inflammatory Bowel Disease Treatment by Disease Indication
10.3.6.5.3 South Korea Inflammatory Bowel Disease Treatment by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Inflammatory Bowel Disease Treatment Overview
10.4.2 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis
10.4.3 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
10.4.5 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
10.4.6.1 South Africa Inflammatory Bowel Disease Treatment
10.4.6.1.1 South Africa Inflammatory Bowel Disease Treatment by Drug Class
10.4.6.1.2 South Africa Inflammatory Bowel Disease Treatment by Disease Indication
10.4.6.1.3 South Africa Inflammatory Bowel Disease Treatment by Distribution Channel
10.4.6.2 Saudi Arabia Inflammatory Bowel Disease Treatment
10.4.6.2.1 Saudi Arabia Inflammatory Bowel Disease Treatment by Drug Class
10.4.6.2.2 Saudi Arabia Inflammatory Bowel Disease Treatment by Disease Indication
10.4.6.2.3 Saudi Arabia Inflammatory Bowel Disease Treatment by Distribution Channel
10.4.6.3 U.A.E Inflammatory Bowel Disease Treatment
10.4.6.3.1 U.A.E Inflammatory Bowel Disease Treatment by Drug Class
10.4.6.3.2 U.A.E Inflammatory Bowel Disease Treatment by Disease Indication
10.4.6.3.3 U.A.E Inflammatory Bowel Disease Treatment by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Inflammatory Bowel Disease Treatment Overview
10.5.2 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis
10.5.3 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
10.5.5 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
10.5.6.1 Brazil Inflammatory Bowel Disease Treatment
10.5.6.1.1 Brazil Inflammatory Bowel Disease Treatment by Drug Class
10.5.6.1.2 Brazil Inflammatory Bowel Disease Treatment by Disease Indication
10.5.6.1.3 Brazil Inflammatory Bowel Disease Treatment by Distribution Channel
10.5.6.2 Argentina Inflammatory Bowel Disease Treatment
10.5.6.2.1 Argentina Inflammatory Bowel Disease Treatment by Drug Class
10.5.6.2.2 Argentina Inflammatory Bowel Disease Treatment by Disease Indication
10.5.6.2.3 Argentina Inflammatory Bowel Disease Treatment by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. INFLAMMATORY BOWEL DISEASE TREATMENT, KEY COMPANY PROFILES
12.1. PFIZER INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. NOVARTIS AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. JOHNSON AND JOHNSON (JANSSEN GLOBAL SERVICES, LLC)
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ABBVIE INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. TAKEDA PHARMACEUTICAL COMPANY LIMITED
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ALLERGAN
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. CELGENE CORPORATION
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. BAUSCH HEALTH
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. UCB, INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. COSMO PHARMACEUTICALS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Inflammatory Bowel Disease Treatment - By Drug Class
1.3.2 Inflammatory Bowel Disease Treatment - By Disease Indication
1.3.3 Inflammatory Bowel Disease Treatment - By Distribution Channel
1.3.4 Inflammatory Bowel Disease Treatment - By Region
1.3.4.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. INFLAMMATORY BOWEL DISEASE TREATMENT LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. INFLAMMATORY BOWEL DISEASE TREATMENT - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. INFLAMMATORY BOWEL DISEASE TREATMENT - GLOBAL MARKET ANALYSIS
6.1. INFLAMMATORY BOWEL DISEASE TREATMENT - GLOBAL MARKET OVERVIEW
6.2. INFLAMMATORY BOWEL DISEASE TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. INFLAMMATORY BOWEL DISEASE TREATMENT - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. AMINOSALICYCLATES
7.3.1. Overview
7.3.2. Aminosalicyclates Market Forecast and Analysis
7.4. IMMUNOMODULATORS
7.4.1. Overview
7.4.2. Immunomodulators Market Forecast and Analysis
7.5. TNF INHIBITORS
7.5.1. Overview
7.5.2. TNF Inhibitors Market Forecast and Analysis
7.6. CORTICOSTEROIDS
7.6.1. Overview
7.6.2. Corticosteroids Market Forecast and Analysis
8. INFLAMMATORY BOWEL DISEASE TREATMENT - REVENUE AND FORECASTS TO 2027 - DISEASE INDICATION
8.1. OVERVIEW
8.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
8.3. CROHN'S DISEASE
8.3.1. Overview
8.3.2. Crohn's Disease Market Forecast and Analysis
8.4. ULCERATIVE COLITIS
8.4.1. Overview
8.4.2. Ulcerative Colitis Market Forecast and Analysis
9. INFLAMMATORY BOWEL DISEASE TREATMENT - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. ONLINE PHARMACY
9.4.1. Overview
9.4.2. Online Pharmacy Market Forecast and Analysis
9.5. RETAIL PHARMACY
9.5.1. Overview
9.5.2. Retail Pharmacy Market Forecast and Analysis
10. INFLAMMATORY BOWEL DISEASE TREATMENT REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Inflammatory Bowel Disease Treatment Overview
10.1.2 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis
10.1.3 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
10.1.4 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
10.1.5 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
10.1.6 North America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
10.1.6.1 United States Inflammatory Bowel Disease Treatment
10.1.6.1.1 United States Inflammatory Bowel Disease Treatment by Drug Class
10.1.6.1.2 United States Inflammatory Bowel Disease Treatment by Disease Indication
10.1.6.1.3 United States Inflammatory Bowel Disease Treatment by Distribution Channel
10.1.6.2 Canada Inflammatory Bowel Disease Treatment
10.1.6.2.1 Canada Inflammatory Bowel Disease Treatment by Drug Class
10.1.6.2.2 Canada Inflammatory Bowel Disease Treatment by Disease Indication
10.1.6.2.3 Canada Inflammatory Bowel Disease Treatment by Distribution Channel
10.1.6.3 Mexico Inflammatory Bowel Disease Treatment
10.1.6.3.1 Mexico Inflammatory Bowel Disease Treatment by Drug Class
10.1.6.3.2 Mexico Inflammatory Bowel Disease Treatment by Disease Indication
10.1.6.3.3 Mexico Inflammatory Bowel Disease Treatment by Distribution Channel
10.2. EUROPE
10.2.1 Europe Inflammatory Bowel Disease Treatment Overview
10.2.2 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis
10.2.3 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
10.2.4 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
10.2.5 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
10.2.6.1 Germany Inflammatory Bowel Disease Treatment
10.2.6.1.1 Germany Inflammatory Bowel Disease Treatment by Drug Class
10.2.6.1.2 Germany Inflammatory Bowel Disease Treatment by Disease Indication
10.2.6.1.3 Germany Inflammatory Bowel Disease Treatment by Distribution Channel
10.2.6.2 France Inflammatory Bowel Disease Treatment
10.2.6.2.1 France Inflammatory Bowel Disease Treatment by Drug Class
10.2.6.2.2 France Inflammatory Bowel Disease Treatment by Disease Indication
10.2.6.2.3 France Inflammatory Bowel Disease Treatment by Distribution Channel
10.2.6.3 Italy Inflammatory Bowel Disease Treatment
10.2.6.3.1 Italy Inflammatory Bowel Disease Treatment by Drug Class
10.2.6.3.2 Italy Inflammatory Bowel Disease Treatment by Disease Indication
10.2.6.3.3 Italy Inflammatory Bowel Disease Treatment by Distribution Channel
10.2.6.4 Spain Inflammatory Bowel Disease Treatment
10.2.6.4.1 Spain Inflammatory Bowel Disease Treatment by Drug Class
10.2.6.4.2 Spain Inflammatory Bowel Disease Treatment by Disease Indication
10.2.6.4.3 Spain Inflammatory Bowel Disease Treatment by Distribution Channel
10.2.6.5 United Kingdom Inflammatory Bowel Disease Treatment
10.2.6.5.1 United Kingdom Inflammatory Bowel Disease Treatment by Drug Class
10.2.6.5.2 United Kingdom Inflammatory Bowel Disease Treatment by Disease Indication
10.2.6.5.3 United Kingdom Inflammatory Bowel Disease Treatment by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Inflammatory Bowel Disease Treatment Overview
10.3.2 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis
10.3.3 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
10.3.5 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
10.3.6.1 Australia Inflammatory Bowel Disease Treatment
10.3.6.1.1 Australia Inflammatory Bowel Disease Treatment by Drug Class
10.3.6.1.2 Australia Inflammatory Bowel Disease Treatment by Disease Indication
10.3.6.1.3 Australia Inflammatory Bowel Disease Treatment by Distribution Channel
10.3.6.2 China Inflammatory Bowel Disease Treatment
10.3.6.2.1 China Inflammatory Bowel Disease Treatment by Drug Class
10.3.6.2.2 China Inflammatory Bowel Disease Treatment by Disease Indication
10.3.6.2.3 China Inflammatory Bowel Disease Treatment by Distribution Channel
10.3.6.3 India Inflammatory Bowel Disease Treatment
10.3.6.3.1 India Inflammatory Bowel Disease Treatment by Drug Class
10.3.6.3.2 India Inflammatory Bowel Disease Treatment by Disease Indication
10.3.6.3.3 India Inflammatory Bowel Disease Treatment by Distribution Channel
10.3.6.4 Japan Inflammatory Bowel Disease Treatment
10.3.6.4.1 Japan Inflammatory Bowel Disease Treatment by Drug Class
10.3.6.4.2 Japan Inflammatory Bowel Disease Treatment by Disease Indication
10.3.6.4.3 Japan Inflammatory Bowel Disease Treatment by Distribution Channel
10.3.6.5 South Korea Inflammatory Bowel Disease Treatment
10.3.6.5.1 South Korea Inflammatory Bowel Disease Treatment by Drug Class
10.3.6.5.2 South Korea Inflammatory Bowel Disease Treatment by Disease Indication
10.3.6.5.3 South Korea Inflammatory Bowel Disease Treatment by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Inflammatory Bowel Disease Treatment Overview
10.4.2 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis
10.4.3 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
10.4.5 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
10.4.6.1 South Africa Inflammatory Bowel Disease Treatment
10.4.6.1.1 South Africa Inflammatory Bowel Disease Treatment by Drug Class
10.4.6.1.2 South Africa Inflammatory Bowel Disease Treatment by Disease Indication
10.4.6.1.3 South Africa Inflammatory Bowel Disease Treatment by Distribution Channel
10.4.6.2 Saudi Arabia Inflammatory Bowel Disease Treatment
10.4.6.2.1 Saudi Arabia Inflammatory Bowel Disease Treatment by Drug Class
10.4.6.2.2 Saudi Arabia Inflammatory Bowel Disease Treatment by Disease Indication
10.4.6.2.3 Saudi Arabia Inflammatory Bowel Disease Treatment by Distribution Channel
10.4.6.3 U.A.E Inflammatory Bowel Disease Treatment
10.4.6.3.1 U.A.E Inflammatory Bowel Disease Treatment by Drug Class
10.4.6.3.2 U.A.E Inflammatory Bowel Disease Treatment by Disease Indication
10.4.6.3.3 U.A.E Inflammatory Bowel Disease Treatment by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Inflammatory Bowel Disease Treatment Overview
10.5.2 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis
10.5.3 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Disease Indication
10.5.5 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Inflammatory Bowel Disease Treatment Forecasts and Analysis - By Countries
10.5.6.1 Brazil Inflammatory Bowel Disease Treatment
10.5.6.1.1 Brazil Inflammatory Bowel Disease Treatment by Drug Class
10.5.6.1.2 Brazil Inflammatory Bowel Disease Treatment by Disease Indication
10.5.6.1.3 Brazil Inflammatory Bowel Disease Treatment by Distribution Channel
10.5.6.2 Argentina Inflammatory Bowel Disease Treatment
10.5.6.2.1 Argentina Inflammatory Bowel Disease Treatment by Drug Class
10.5.6.2.2 Argentina Inflammatory Bowel Disease Treatment by Disease Indication
10.5.6.2.3 Argentina Inflammatory Bowel Disease Treatment by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. INFLAMMATORY BOWEL DISEASE TREATMENT, KEY COMPANY PROFILES
12.1. PFIZER INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. NOVARTIS AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. JOHNSON AND JOHNSON (JANSSEN GLOBAL SERVICES, LLC)
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ABBVIE INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. TAKEDA PHARMACEUTICAL COMPANY LIMITED
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ALLERGAN
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. CELGENE CORPORATION
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. BAUSCH HEALTH
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. UCB, INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. COSMO PHARMACEUTICALS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies
1. Pfizer Inc.
2. Novartis AG
3. JOHNSON & JOHNSON (Janssen Global Services, LLC)
4. AbbVie Inc.
5. Takeda Pharmaceutical Company Limited
6. ALLERGAN
7. CELGENE CORPORATION
8. Bausch Health
9. UCB, Inc.
10. COSMO PHARMACEUTICALS
1. Pfizer Inc.
2. Novartis AG
3. JOHNSON & JOHNSON (Janssen Global Services, LLC)
4. AbbVie Inc.
5. Takeda Pharmaceutical Company Limited
6. ALLERGAN
7. CELGENE CORPORATION
8. Bausch Health
9. UCB, Inc.
10. COSMO PHARMACEUTICALS